<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
>
<channel>
	<title>Ancell Corporation</title>
	<atom:link href="http://http://www.ancell.com/Array" rel="self" type="application/rss+xml" />
	<link>http://www.ancell.com/Array</link>
	<description>Ancell Corporation</description>
	<lastBuildDate>Wed, 19 Jun 2013 18:55:31 -0500</lastBuildDate>

	<generator>http://room34.com/</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	
				<item>
				<title>anti-CD105 fluorescent conjugates for phenotypic analysis of Mesenchymal Stem Cells</title>
				<link>http://www.ancell.com/posts//25</link>
				<comments>http://www.ancell.com/posts//25#comments</comments>
				<pubDate>Fri, 14 Jun 2013 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//25</guid>
				<description><![CDATA[<p class="MsoNormal">Featured product: Ancell <a href="http://www.ancell.com/store/item/610">anti-CD105/FITC clone SN6</a></p>
<p class="MsoNormal">In these studies, Mesenchymal Stem/Progenitor cells show potential for repairing damaged joint tissue, and restoring liver function.&nbsp; After enriched by sorting, and expansion in culture, the phenotype of resulting stem cell populations are:&nbsp; CD105+, CD29+, CD166+, CD44+, CD45-, CD31-.</p>
<p><span class="maintitle">1) <a href="http://onlinelibrary.wiley.com/doi/10.1002/hep.21704/full">&ldquo;Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes<sup>&rdquo; </sup>&nbsp;A Banas, T Ochiya, et al. (2007) Hepatology 46: 219-228.</a></span></p>
<p>2)<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0013246">&ldquo;Identification and Clonal Characterisation of a Progenitor Cell Sub-Population in Normal Human Articular Cartilage&rdquo; R Williams, HE McCathy, et al. (2010) PLoS ONE 5(10): e13246&nbsp; doi:10.1371.</a>&nbsp;</p>
<p class="MsoNormal">3)<a href="http://onlinelibrary.wiley.com/doi/10.1002/art.20269/pdf">&ldquo;Identification of Mesenchymal Progenitor Cells in Normal and Osteoarthritic Human Articular Cartilage&rdquo; S Alsalameh, M Lotz, et al. (2004) Arthritis &amp; Rhematism 50(5): 1522-1532.</a></p>
<p>Related Ancell Products</p>
<p><a href="http://www.ancell.com/store/search?s=CD105">anti-CD105</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD166">anti-CD166</a></p>
<p><a href="http://www.ancell.com/store/search?s=Antibody+C11+recognizes+all+isoforms+of+CD45">anti-CD45</a></p>
<p><a href="http://www.ancell.com/store/search?s=Antibody+4B7R+recognizes+the+CD29+integrin+subunit.">anti-CD29</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD44">anti-CD44</a></p>]]></description>
				<content:encoded><![CDATA[<p class="MsoNormal">Featured product: Ancell <a href="http://www.ancell.com/store/item/610">anti-CD105/FITC clone SN6</a></p>
<p class="MsoNormal">In these studies, Mesenchymal Stem/Progenitor cells show potential for repairing damaged joint tissue, and restoring liver function.&nbsp; After enriched by sorting, and expansion in culture, the phenotype of resulting stem cell populations are:&nbsp; CD105+, CD29+, CD166+, CD44+, CD45-, CD31-.</p>
<p><span class="maintitle">1) <a href="http://onlinelibrary.wiley.com/doi/10.1002/hep.21704/full">&ldquo;Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes<sup>&rdquo; </sup>&nbsp;A Banas, T Ochiya, et al. (2007) Hepatology 46: 219-228.</a></span></p>
<p>2)<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0013246">&ldquo;Identification and Clonal Characterisation of a Progenitor Cell Sub-Population in Normal Human Articular Cartilage&rdquo; R Williams, HE McCathy, et al. (2010) PLoS ONE 5(10): e13246&nbsp; doi:10.1371.</a>&nbsp;</p>
<p class="MsoNormal">3)<a href="http://onlinelibrary.wiley.com/doi/10.1002/art.20269/pdf">&ldquo;Identification of Mesenchymal Progenitor Cells in Normal and Osteoarthritic Human Articular Cartilage&rdquo; S Alsalameh, M Lotz, et al. (2004) Arthritis &amp; Rhematism 50(5): 1522-1532.</a></p>
<p>Related Ancell Products</p>
<p><a href="http://www.ancell.com/store/search?s=CD105">anti-CD105</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD166">anti-CD166</a></p>
<p><a href="http://www.ancell.com/store/search?s=Antibody+C11+recognizes+all+isoforms+of+CD45">anti-CD45</a></p>
<p><a href="http://www.ancell.com/store/search?s=Antibody+4B7R+recognizes+the+CD29+integrin+subunit.">anti-CD29</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD44">anti-CD44</a></p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/25</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>Biotinylated mAb cocktail effective for isolating Low Density Granulocytes from SLE patient blood</title>
				<link>http://www.ancell.com/posts//24</link>
				<comments>http://www.ancell.com/posts//24#comments</comments>
				<pubDate>Thu, 02 May 2013 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//24</guid>
				<description><![CDATA[<p class="MsoNormal"><strong>Featured product: Ancell Biotinylated mAb cocktail effective for Negative selection of Low Density Granulocyte(LDG) population from Systemic Lupus Erythematosis (SLE) patient blood.</strong></p>
<p class="MsoNormal"><span class="citation-flpages"><strong>&ldquo;</strong></span><strong><a href="http://www.jimmunol.org/content/184/6/3284.long">A Distinct Subset of Proinflammatory Neutrophils Isolated from Patients with Systemic Lupus Erythematosus Induces Vascular Damage and Synthesizes Type I IFNs &ldquo;</a></strong></p>
<p class="MsoNormal"><span class="MsoHyperlink"><a href="http://www.jimmunol.org/content/184/6/3284.long">M.F. Denny, M.J. Kaplan, et al.<span>&nbsp; </span>(2010) J Immunol <span><span>&nbsp;</span><strong>184</strong>(6): 3284-3297</span></a></span><span class="slug-pages"><span> </span></span></p>
<p class="MsoNormal"><span class="slug-pages"><span>&nbsp;</span></span></p>
<p class="MsoNormal"><span class="slug-pages"><span>This University of Michigan group has used a Biotinylated antibody cocktail in conjunction with anti-Biotin MACS beads to quickly isolate and characterize this unusual population of neutrophils from ficoll prepared, RBC-lysed Systemic Lupus Erythematosus patient blood.<span>&nbsp; </span>Purity of isolated cells was determined as &gt;95% CD10+, CD15+/CD14lo.</span></span></p>
<p class="MsoNormal"><span class="slug-pages"><span><span>&nbsp;</span>Isolated low density granulocytes (LDG) have capacity to interfere with differentiation of Endothelial precursors.<span>&nbsp; </span>While LDG have impaired phagocytic function, they are cytotoxic to vascular endothelium. LDG also exhibit enhanced extracellular trap (NET) ability.<span>&nbsp; </span>This cell population may play a significant role in SLE progression.</span></span></p>
<p class="MsoNormal"><span class="slug-pages"><span>&nbsp;</span></span></p>
<p class="MsoNormal"><span class="slug-pages"><strong><span>Ancell Biotinylated mAbs for negative selection of LDG </span></strong></span></p>
<p class="MsoNormal"><span class="slug-pages"><span><a href="http://www.ancell.com/store/item/71">anti-CD3</a>, <a href="http://www.ancell.com/store/item/110">anti-CD7</a>, <a href="http://www.ancell.com/store/item/186">anti-CD19</a>, <a href="http://www.ancell.com/store/item/554">anti-CD79b</a>, <a href="http://www.ancell.com/store/item/579">anti-CD56</a>, <a href="http://www.ancell.com/store/item/30">anti-MHC Class II</a>, <a href="http://www.ancell.com/store/item/574">anti-CD86</a>, <a href="http://www.ancell.com/store/item/26">anti-CD235</a>a</span></span></p>]]></description>
				<content:encoded><![CDATA[<p class="MsoNormal"><strong>Featured product: Ancell Biotinylated mAb cocktail effective for Negative selection of Low Density Granulocyte(LDG) population from Systemic Lupus Erythematosis (SLE) patient blood.</strong></p>
<p class="MsoNormal"><span class="citation-flpages"><strong>&ldquo;</strong></span><strong><a href="http://www.jimmunol.org/content/184/6/3284.long">A Distinct Subset of Proinflammatory Neutrophils Isolated from Patients with Systemic Lupus Erythematosus Induces Vascular Damage and Synthesizes Type I IFNs &ldquo;</a></strong></p>
<p class="MsoNormal"><span class="MsoHyperlink"><a href="http://www.jimmunol.org/content/184/6/3284.long">M.F. Denny, M.J. Kaplan, et al.<span>&nbsp; </span>(2010) J Immunol <span><span>&nbsp;</span><strong>184</strong>(6): 3284-3297</span></a></span><span class="slug-pages"><span> </span></span></p>
<p class="MsoNormal"><span class="slug-pages"><span>&nbsp;</span></span></p>
<p class="MsoNormal"><span class="slug-pages"><span>This University of Michigan group has used a Biotinylated antibody cocktail in conjunction with anti-Biotin MACS beads to quickly isolate and characterize this unusual population of neutrophils from ficoll prepared, RBC-lysed Systemic Lupus Erythematosus patient blood.<span>&nbsp; </span>Purity of isolated cells was determined as &gt;95% CD10+, CD15+/CD14lo.</span></span></p>
<p class="MsoNormal"><span class="slug-pages"><span><span>&nbsp;</span>Isolated low density granulocytes (LDG) have capacity to interfere with differentiation of Endothelial precursors.<span>&nbsp; </span>While LDG have impaired phagocytic function, they are cytotoxic to vascular endothelium. LDG also exhibit enhanced extracellular trap (NET) ability.<span>&nbsp; </span>This cell population may play a significant role in SLE progression.</span></span></p>
<p class="MsoNormal"><span class="slug-pages"><span>&nbsp;</span></span></p>
<p class="MsoNormal"><span class="slug-pages"><strong><span>Ancell Biotinylated mAbs for negative selection of LDG </span></strong></span></p>
<p class="MsoNormal"><span class="slug-pages"><span><a href="http://www.ancell.com/store/item/71">anti-CD3</a>, <a href="http://www.ancell.com/store/item/110">anti-CD7</a>, <a href="http://www.ancell.com/store/item/186">anti-CD19</a>, <a href="http://www.ancell.com/store/item/554">anti-CD79b</a>, <a href="http://www.ancell.com/store/item/579">anti-CD56</a>, <a href="http://www.ancell.com/store/item/30">anti-MHC Class II</a>, <a href="http://www.ancell.com/store/item/574">anti-CD86</a>, <a href="http://www.ancell.com/store/item/26">anti-CD235</a>a</span></span></p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/24</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>CD64 Fc&amp;amp;gamma;RI, CD32Fc&amp;amp;gamma;RII, CD16Fc&amp;amp;gamma;RIII F(ab&amp;acirc;€™)2</title>
				<link>http://www.ancell.com/posts//23</link>
				<comments>http://www.ancell.com/posts//23#comments</comments>
				<pubDate>Mon, 08 Apr 2013 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//23</guid>
				<description><![CDATA[<p><strong>Featured Products: F(ab&rsquo;)<sub>2</sub> Fragments of anti-CD64(Fc</strong><strong>gRI), anti-CD32(Fc</strong><strong>gRII), and anti-CD16(Fc</strong><strong>gRIII) for Human Fc Receptor and Immune Complex &nbsp;Research </strong></p>
<p>Low Endotoxin and Essentially Free of Intact Antibody, these dimericantibody fragments block Immunoglobulin binding to their repective receptors</p>
<p><a href="http://www.ancell.com/store/item/401">anti-human CD64 (FcgRI)F(ab&rsquo;)<sub>2</sub></a><a href="http://www.ancell.com/store/item/401"> clone 10.1 </a></p>
<p><a href="http://www.ancell.com/store/item/254">anti-human CD32 (FcgRII) F(ab&rsquo;)<sub>2</sub></a><a href="http://www.ancell.com/store/item/254"> clone 7.3</a></p>
<p><a href="http://www.ancell.com/store/item/172">anti-human CD16 (FcgRIII) F(ab&rsquo;)<sub>2</sub></a><a href="http://www.ancell.com/store/item/172"> clone 3G8</a></p>
<p><strong>Literature Citations </strong></p>
<p>Inhibition of Fibrocyte differentiation</p>
<p><a href="http://www.jleukbio.org/content/79/6/1242.long">D Pilling, N M Tucker, R H Gomer (2006) <em>J Leuk Bio</em>l <strong>79</strong>(6): 1242-1251.</a></p>
<p>&nbsp;</p>
<p>Modulation of Dendritic cell response to microbial infection</p>
<p><a href="http://intimm.oxfordjournals.org/content/16/1/149.full">L Romani, P Puccetti, et al. (2004) <em>Int Immunol</em> <strong>16</strong>(1): 149-161.</a></p>
<p>&nbsp;</p>
<p>Modulation of Dendritic cell maturation</p>
<p><a href="http://www.jimmunol.org/content/179/1/673.long">E A Laborde, M Vulcano, et al. (2007) <em>J Immunol</em> <strong>179</strong>(1): 673-81.</a></p>
<p>&nbsp;</p>
<p>anti-CD16 F(ab&rsquo;)<sub>2 &nbsp;</sub>Mac-1 upregulation in Neutrophils</p>
<p><a href="http://bloodjournal.hematologylibrary.org/content/112/4/1091.full.pdf">Z Xiao, S Neelamegham, et al. (2008) Blood 112: 1091-1100.</a></p>]]></description>
				<content:encoded><![CDATA[<p><strong>Featured Products: F(ab&rsquo;)<sub>2</sub> Fragments of anti-CD64(Fc</strong><strong>gRI), anti-CD32(Fc</strong><strong>gRII), and anti-CD16(Fc</strong><strong>gRIII) for Human Fc Receptor and Immune Complex &nbsp;Research </strong></p>
<p>Low Endotoxin and Essentially Free of Intact Antibody, these dimericantibody fragments block Immunoglobulin binding to their repective receptors</p>
<p><a href="http://www.ancell.com/store/item/401">anti-human CD64 (FcgRI)F(ab&rsquo;)<sub>2</sub></a><a href="http://www.ancell.com/store/item/401"> clone 10.1 </a></p>
<p><a href="http://www.ancell.com/store/item/254">anti-human CD32 (FcgRII) F(ab&rsquo;)<sub>2</sub></a><a href="http://www.ancell.com/store/item/254"> clone 7.3</a></p>
<p><a href="http://www.ancell.com/store/item/172">anti-human CD16 (FcgRIII) F(ab&rsquo;)<sub>2</sub></a><a href="http://www.ancell.com/store/item/172"> clone 3G8</a></p>
<p><strong>Literature Citations </strong></p>
<p>Inhibition of Fibrocyte differentiation</p>
<p><a href="http://www.jleukbio.org/content/79/6/1242.long">D Pilling, N M Tucker, R H Gomer (2006) <em>J Leuk Bio</em>l <strong>79</strong>(6): 1242-1251.</a></p>
<p>&nbsp;</p>
<p>Modulation of Dendritic cell response to microbial infection</p>
<p><a href="http://intimm.oxfordjournals.org/content/16/1/149.full">L Romani, P Puccetti, et al. (2004) <em>Int Immunol</em> <strong>16</strong>(1): 149-161.</a></p>
<p>&nbsp;</p>
<p>Modulation of Dendritic cell maturation</p>
<p><a href="http://www.jimmunol.org/content/179/1/673.long">E A Laborde, M Vulcano, et al. (2007) <em>J Immunol</em> <strong>179</strong>(1): 673-81.</a></p>
<p>&nbsp;</p>
<p>anti-CD16 F(ab&rsquo;)<sub>2 &nbsp;</sub>Mac-1 upregulation in Neutrophils</p>
<p><a href="http://bloodjournal.hematologylibrary.org/content/112/4/1091.full.pdf">Z Xiao, S Neelamegham, et al. (2008) Blood 112: 1091-1100.</a></p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/23</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>Recombinant CD273-muIg</title>
				<link>http://www.ancell.com/posts//22</link>
				<comments>http://www.ancell.com/posts//22#comments</comments>
				<pubDate>Fri, 29 Mar 2013 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//22</guid>
				<description><![CDATA[<p>New human biologically active <a href="http://www.ancell.com/store/search?s=CD273">CD273 ( B7-DC, PD-L2) recombinant protein and other related products</a> now available!</p>]]></description>
				<content:encoded><![CDATA[<p>New human biologically active <a href="http://www.ancell.com/store/search?s=CD273">CD273 ( B7-DC, PD-L2) recombinant protein and other related products</a> now available!</p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/22</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>Cell Surface Metastatic Markers for Colon Cancer SW480/SW620 Model</title>
				<link>http://www.ancell.com/posts//21</link>
				<comments>http://www.ancell.com/posts//21#comments</comments>
				<pubDate>Fri, 01 Feb 2013 00:00:00 -0600</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//21</guid>
				<description><![CDATA[<p><a href="http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=CCL-228&amp;Template=cellBiology">SW480</a> is a primary Colon Epithelial Adenocarcinoma tumor line and <a href="http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=CCL-227&amp;Template=cellBiology">SW620</a> is a metastasized variant of this derived from lymph node.&nbsp; Differential analysis of surface markers may give insight into tumor metastatic potential and/or mechanisms.</p>
<p>&nbsp;</p>
<p><strong><a href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0053015">&ldquo;Multiplex Flow Cytometry Barcoding and Antibody Arrays Identify Surface Antigen Profiles of Primary and Metastatic Colon Cancer Cell Lines&rdquo;</a></strong></p>
<p><a href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0053015">K Sukhedeo, J.N. Rich, et al. (2013) <em>PLOSone</em> <strong>8</strong>(1): e53015.</a></p>
<p>&nbsp;</p>
<p><strong>Relevant Ancell Antibody Products</strong></p>
<p><strong>Antigens Upregulated after metastasis</strong></p>
<p><a href="http://www.ancell.com/store/search?s=CD10">CD10</a></p>
<p><a href="http://www.ancell.com/store/search?s=QS4120">CD4</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD43">CD43</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD24">CD24</a></p>
<p>&nbsp;</p>
<p><strong>Antigens Downregulated after metastasis</strong></p>
<p><a href="http://www.ancell.com/store/search?s=BU33">CD21</a></p>
<p><a href="http://www.ancell.com/store/item/581">CD56</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD57">CD57</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD162">CD162</a></p>
<p><a href="http://www.ancell.com/store/search?s=3A1e">CD7</a></p>
<p><a href="http://www.ancell.com/store/search?s=BU69">CD70</a></p>
<p><a href="http://www.ancell.com/store/search?s=UCHT1">CD3</a></p>
<p><a href="http://www.ancell.com/store/search?s=ANC95.1%2FE2">CD95</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD43">CD33</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD45RA">CD45RA</a></p>
<p><a href="http://www.ancell.com/store/search?s=SN8%2F3A2-2E7">CD79b</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD100">CD100</a></p>
<p><a href="http://www.ancell.com/store/search?s=ANC271%2F3D7">CD271</a></p>
<p><a href="http://www.ancell.com/store/search?s=UMCD6%2F3F7B5+">CD6</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD75">CD75</a></p>
<p><a href="http://www.ancell.com/store/search?s=15.2">CD54</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD55">CD55</a></p>
<p>&nbsp;</p>
<p>&nbsp;</p>]]></description>
				<content:encoded><![CDATA[<p><a href="http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=CCL-228&amp;Template=cellBiology">SW480</a> is a primary Colon Epithelial Adenocarcinoma tumor line and <a href="http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=CCL-227&amp;Template=cellBiology">SW620</a> is a metastasized variant of this derived from lymph node.&nbsp; Differential analysis of surface markers may give insight into tumor metastatic potential and/or mechanisms.</p>
<p>&nbsp;</p>
<p><strong><a href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0053015">&ldquo;Multiplex Flow Cytometry Barcoding and Antibody Arrays Identify Surface Antigen Profiles of Primary and Metastatic Colon Cancer Cell Lines&rdquo;</a></strong></p>
<p><a href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0053015">K Sukhedeo, J.N. Rich, et al. (2013) <em>PLOSone</em> <strong>8</strong>(1): e53015.</a></p>
<p>&nbsp;</p>
<p><strong>Relevant Ancell Antibody Products</strong></p>
<p><strong>Antigens Upregulated after metastasis</strong></p>
<p><a href="http://www.ancell.com/store/search?s=CD10">CD10</a></p>
<p><a href="http://www.ancell.com/store/search?s=QS4120">CD4</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD43">CD43</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD24">CD24</a></p>
<p>&nbsp;</p>
<p><strong>Antigens Downregulated after metastasis</strong></p>
<p><a href="http://www.ancell.com/store/search?s=BU33">CD21</a></p>
<p><a href="http://www.ancell.com/store/item/581">CD56</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD57">CD57</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD162">CD162</a></p>
<p><a href="http://www.ancell.com/store/search?s=3A1e">CD7</a></p>
<p><a href="http://www.ancell.com/store/search?s=BU69">CD70</a></p>
<p><a href="http://www.ancell.com/store/search?s=UCHT1">CD3</a></p>
<p><a href="http://www.ancell.com/store/search?s=ANC95.1%2FE2">CD95</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD43">CD33</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD45RA">CD45RA</a></p>
<p><a href="http://www.ancell.com/store/search?s=SN8%2F3A2-2E7">CD79b</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD100">CD100</a></p>
<p><a href="http://www.ancell.com/store/search?s=ANC271%2F3D7">CD271</a></p>
<p><a href="http://www.ancell.com/store/search?s=UMCD6%2F3F7B5+">CD6</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD75">CD75</a></p>
<p><a href="http://www.ancell.com/store/search?s=15.2">CD54</a></p>
<p><a href="http://www.ancell.com/store/search?s=CD55">CD55</a></p>
<p>&nbsp;</p>
<p>&nbsp;</p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/21</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>New anti-CD269 (BCMA) antibody availible!</title>
				<link>http://www.ancell.com/posts//20</link>
				<comments>http://www.ancell.com/posts//20#comments</comments>
				<pubDate>Wed, 05 Dec 2012 00:00:00 -0600</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//20</guid>
				<description><![CDATA[<p><strong>New anti-CD269 (BCMA) antibody availible!</strong></p>
<p>&nbsp;</p>
<p>Purified &nbsp;(with antibiotic)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;<a href="http://www.ancell.com/store/item/898">catalog # 269-020</a></p>
<p>&nbsp;</p>
<p>Purified &nbsp;(preservative-free)&nbsp; <a href="http://www.ancell.com/store/item/899">catalog # 269-020</a></p>]]></description>
				<content:encoded><![CDATA[<p><strong>New anti-CD269 (BCMA) antibody availible!</strong></p>
<p>&nbsp;</p>
<p>Purified &nbsp;(with antibiotic)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;<a href="http://www.ancell.com/store/item/898">catalog # 269-020</a></p>
<p>&nbsp;</p>
<p>Purified &nbsp;(preservative-free)&nbsp; <a href="http://www.ancell.com/store/item/899">catalog # 269-020</a></p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/20</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>Ancell at AIC in Chicago</title>
				<link>http://www.ancell.com/posts//19</link>
				<comments>http://www.ancell.com/posts//19#comments</comments>
				<pubDate>Tue, 13 Nov 2012 00:00:00 -0600</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//19</guid>
				<description><![CDATA[<p>Ancell is proud to be a <a href="http://www.autumnimmunology.org/sponsors.php">sponsor</a> of the <a href="http://www.autumnimmunology.org/">2012 Autumn Immunology Conference</a> in Chicago Nov 16th -Nov 19th.</p>
<p>Visit us at booth #18!</p>
<p>&nbsp;</p>]]></description>
				<content:encoded><![CDATA[<p>Ancell is proud to be a <a href="http://www.autumnimmunology.org/sponsors.php">sponsor</a> of the <a href="http://www.autumnimmunology.org/">2012 Autumn Immunology Conference</a> in Chicago Nov 16th -Nov 19th.</p>
<p>Visit us at booth #18!</p>
<p>&nbsp;</p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/19</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>Clinical Response to Prostate Cancer Immunotherapy using GM-CSF and anti-CD152 Correlates with Diversity of Upmodulated Antibody Binding to Microarray Antigens</title>
				<link>http://www.ancell.com/posts//18</link>
				<comments>http://www.ancell.com/posts//18#comments</comments>
				<pubDate>Fri, 05 Oct 2012 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//18</guid>
				<description><![CDATA[<p><a href="http://www.ncbi.nlm.nih.gov/pubmed/22956585">&ldquo;Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients&rdquo;&nbsp;&nbsp; Kwek S S, L Fong, et al. (Oct 2012)&nbsp; <em>J Immunol</em> <strong>189</strong>(7): 3759-3766.</a></p>
<p>&nbsp;&ldquo;&hellip;advanced prostate cancer patients who clinically respond to treatment also develop enhanced Ab responses to a higher number of Ags than nonresponders&hellip;&rdquo;</p>
<p><strong>Relevant Ancell Products</strong></p>
<p><a href="http://www.ancell.com/store/item/660">Anti-CD152(CTLA-4) blocking mAb</a></p>
<p><a href="http://www.ancell.com/store/item/730">Recombinant CD152-muIg</a></p>
<p><a href="http://www.ancell.com/store/item/760">Recombinant CD80-muIg</a></p>
<p><a href="http://www.ancell.com/store/item/881">Recombinant CD86-muIg</a></p>]]></description>
				<content:encoded><![CDATA[<p><a href="http://www.ncbi.nlm.nih.gov/pubmed/22956585">&ldquo;Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients&rdquo;&nbsp;&nbsp; Kwek S S, L Fong, et al. (Oct 2012)&nbsp; <em>J Immunol</em> <strong>189</strong>(7): 3759-3766.</a></p>
<p>&nbsp;&ldquo;&hellip;advanced prostate cancer patients who clinically respond to treatment also develop enhanced Ab responses to a higher number of Ags than nonresponders&hellip;&rdquo;</p>
<p><strong>Relevant Ancell Products</strong></p>
<p><a href="http://www.ancell.com/store/item/660">Anti-CD152(CTLA-4) blocking mAb</a></p>
<p><a href="http://www.ancell.com/store/item/730">Recombinant CD152-muIg</a></p>
<p><a href="http://www.ancell.com/store/item/760">Recombinant CD80-muIg</a></p>
<p><a href="http://www.ancell.com/store/item/881">Recombinant CD86-muIg</a></p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/18</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>CD49d is a useful marker for sorting FoxP3+ human Treg</title>
				<link>http://www.ancell.com/posts//17</link>
				<comments>http://www.ancell.com/posts//17#comments</comments>
				<pubDate>Mon, 17 Sep 2012 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//17</guid>
				<description><![CDATA[<p><a href="http://bloodjournal.hematologylibrary.org/content/113/4/827.full.pdf">&rdquo;CD49d provides access to &ldquo;untouched&rdquo; human Foxp3 Treg free of contaminating effector cells&rdquo; Kleinewietfeld M, K Falk, et al. (2012) <em>Blood</em> <strong>113</strong>(4): 827-836.</a></p>
<p>&nbsp;</p>
<p>Magnetic depletion of PBMC using anti-CD127 (Clone hIL7R-M21) and anti-CD49d (Clone BU49) mAbs to yield a pure population of Foxp3 + Treg cells!</p>
<p>&nbsp;</p>
<p><strong>Relevant Ancell products</strong>:&nbsp;</p>
<p><a href="http://www.ancell.com/store/item/337">anti-CD49d (clone BU49)</a></p>
<p><a href="http://www.ancell.com/store/item/625">anti-CD127 (clone ANC8F2)</a></p>
<p><a href="http://www.ancell.com/store/search?s=ANC2E11">anti-Interferon gamma</a></p>
<p><a href="http://www.ancell.com/store/search?s=QS4120">anti-CD4</a></p>
<p><a href="http://www.ancell.com/store/search?s=7G7B6">anti-CD25</a></p>
<p>&nbsp;</p>]]></description>
				<content:encoded><![CDATA[<p><a href="http://bloodjournal.hematologylibrary.org/content/113/4/827.full.pdf">&rdquo;CD49d provides access to &ldquo;untouched&rdquo; human Foxp3 Treg free of contaminating effector cells&rdquo; Kleinewietfeld M, K Falk, et al. (2012) <em>Blood</em> <strong>113</strong>(4): 827-836.</a></p>
<p>&nbsp;</p>
<p>Magnetic depletion of PBMC using anti-CD127 (Clone hIL7R-M21) and anti-CD49d (Clone BU49) mAbs to yield a pure population of Foxp3 + Treg cells!</p>
<p>&nbsp;</p>
<p><strong>Relevant Ancell products</strong>:&nbsp;</p>
<p><a href="http://www.ancell.com/store/item/337">anti-CD49d (clone BU49)</a></p>
<p><a href="http://www.ancell.com/store/item/625">anti-CD127 (clone ANC8F2)</a></p>
<p><a href="http://www.ancell.com/store/search?s=ANC2E11">anti-Interferon gamma</a></p>
<p><a href="http://www.ancell.com/store/search?s=QS4120">anti-CD4</a></p>
<p><a href="http://www.ancell.com/store/search?s=7G7B6">anti-CD25</a></p>
<p>&nbsp;</p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/17</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>PD-1 engagement enhances anti-tumor vaccine in mice</title>
				<link>http://www.ancell.com/posts//16</link>
				<comments>http://www.ancell.com/posts//16#comments</comments>
				<pubDate>Wed, 05 Sep 2012 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//16</guid>
				<description><![CDATA[<p><a href="http://www.ncbi.nlm.nih.gov/pubmed/22837483">&ldquo;B7-DC-Ig Enhances Vaccine Effect by a Novel Mechanism Dependent on PD-1 Expression level on T Cell Subsets&rdquo;</a></p>
<p>M. Mkrtichyan,&nbsp; S.N. Khleif, et al. (2012) <em>J Immunol</em> <strong>189</strong>(5): 2338-2347.</p>
<p>&nbsp;</p>
<p>Engagement of CD279(PD-1) by recombinant CD273 (B7-DC)-muIg enhances effect of anti-tumor vaccine in mice.</p>
<p>Two proposed mechanisms by which this recombinant protein may augment anti tumor vaccine effect: 1) It &nbsp;inhibits proliferation of PD-1high CD4+ T cells, thereby reducing the number of T reg cells within the tumor.&nbsp; 2) It decreases the number of exhausted CD8+ T cells which leads to a better tumor specific cytotoxic response.</p>
<p>&nbsp;</p>
<p><strong>Related Ancell Products</strong></p>
<p>&nbsp;</p>
<p><a href="http://www.ancell.com/store/item/875">Anti-human CD279(PD-1) antibody</a></p>
<p><a href="http://www.ancell.com/store/item/813">Recombinant CD274(B7-H1)-muIg</a></p>]]></description>
				<content:encoded><![CDATA[<p><a href="http://www.ncbi.nlm.nih.gov/pubmed/22837483">&ldquo;B7-DC-Ig Enhances Vaccine Effect by a Novel Mechanism Dependent on PD-1 Expression level on T Cell Subsets&rdquo;</a></p>
<p>M. Mkrtichyan,&nbsp; S.N. Khleif, et al. (2012) <em>J Immunol</em> <strong>189</strong>(5): 2338-2347.</p>
<p>&nbsp;</p>
<p>Engagement of CD279(PD-1) by recombinant CD273 (B7-DC)-muIg enhances effect of anti-tumor vaccine in mice.</p>
<p>Two proposed mechanisms by which this recombinant protein may augment anti tumor vaccine effect: 1) It &nbsp;inhibits proliferation of PD-1high CD4+ T cells, thereby reducing the number of T reg cells within the tumor.&nbsp; 2) It decreases the number of exhausted CD8+ T cells which leads to a better tumor specific cytotoxic response.</p>
<p>&nbsp;</p>
<p><strong>Related Ancell Products</strong></p>
<p>&nbsp;</p>
<p><a href="http://www.ancell.com/store/item/875">Anti-human CD279(PD-1) antibody</a></p>
<p><a href="http://www.ancell.com/store/item/813">Recombinant CD274(B7-H1)-muIg</a></p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/16</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>In vivo Treg proliferation from IL-2 signaling alone</title>
				<link>http://www.ancell.com/posts//15</link>
				<comments>http://www.ancell.com/posts//15#comments</comments>
				<pubDate>Thu, 19 Jul 2012 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//15</guid>
				<description><![CDATA[<p><strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/22623329">Cutting Edge: IL-2 Signals Determine the Degree of TCR Signaling Necessary To Support Regulatory T Cell Proliferation In Vivo.</a></strong></p>
<p>Zou T, Kambayashi T. et al.<em> J Immunol.</em> 2012 Jul 1;<strong>189</strong>(1):28-32.</p>
<p>It has been thought that proliferation of T regulatory cells in vivo was dependent on signaling from T cell receptor &ndash;MHC Class II interaction.&nbsp; Zou and colleagues report proliferative response of adoptively transferred Treg in MHC knockout recipient mice receiving IL-2 immune complex.&nbsp; A similar effect was observed when STAT5 induced Treg were transferred.&nbsp;</p>]]></description>
				<content:encoded><![CDATA[<p><strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/22623329">Cutting Edge: IL-2 Signals Determine the Degree of TCR Signaling Necessary To Support Regulatory T Cell Proliferation In Vivo.</a></strong></p>
<p>Zou T, Kambayashi T. et al.<em> J Immunol.</em> 2012 Jul 1;<strong>189</strong>(1):28-32.</p>
<p>It has been thought that proliferation of T regulatory cells in vivo was dependent on signaling from T cell receptor &ndash;MHC Class II interaction.&nbsp; Zou and colleagues report proliferative response of adoptively transferred Treg in MHC knockout recipient mice receiving IL-2 immune complex.&nbsp; A similar effect was observed when STAT5 induced Treg were transferred.&nbsp;</p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/15</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>CD4+ CD26(bright) Human T cells display Th17 phenotype</title>
				<link>http://www.ancell.com/posts//14</link>
				<comments>http://www.ancell.com/posts//14#comments</comments>
				<pubDate>Fri, 25 May 2012 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//14</guid>
				<description><![CDATA[<p><strong>&ldquo;Human Th17 Cells Express High Levels of Enzymatically active Dipeptidylpeptidase IV (CD26)&rdquo;</strong></p>
<p><strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/22539793">Bengsch B, R Thimme, et al, (2012) J Immunol 188(11): 5438-5447.</a></strong></p>
<p>In transwell assays, CD26(bright) Th17 cells inhibited chemotaxis of CXCR4+ Th1 T cells towards CXCL12.&nbsp;&nbsp;</p>
<p>CD26 appears to be an interesting and useful marker for Th17 autoimmunity.</p>
<p><a href="http://www.ancell.com/store/search?s=anti-CD26">Ancell anti-CD26 reagents (clone 202.36):</a></p>
<p><a href="http://www.ancell.com/store/item/220">Purified anti-CD26</a></p>
<p><a href="http://www.ancell.com/store/item/220">Purified Preservative-free anti-CD26</a></p>
<p><a href="http://www.ancell.com/store/item/221">anti-CD26/Biotin</a></p>
<p><a href="http://www.ancell.com/store/item/222">anti-CD26/FITC</a></p>
<p><a href="http://www.ancell.com/store/item/223">anti-CD26/Phycoerythrin</a></p>]]></description>
				<content:encoded><![CDATA[<p><strong>&ldquo;Human Th17 Cells Express High Levels of Enzymatically active Dipeptidylpeptidase IV (CD26)&rdquo;</strong></p>
<p><strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/22539793">Bengsch B, R Thimme, et al, (2012) J Immunol 188(11): 5438-5447.</a></strong></p>
<p>In transwell assays, CD26(bright) Th17 cells inhibited chemotaxis of CXCR4+ Th1 T cells towards CXCL12.&nbsp;&nbsp;</p>
<p>CD26 appears to be an interesting and useful marker for Th17 autoimmunity.</p>
<p><a href="http://www.ancell.com/store/search?s=anti-CD26">Ancell anti-CD26 reagents (clone 202.36):</a></p>
<p><a href="http://www.ancell.com/store/item/220">Purified anti-CD26</a></p>
<p><a href="http://www.ancell.com/store/item/220">Purified Preservative-free anti-CD26</a></p>
<p><a href="http://www.ancell.com/store/item/221">anti-CD26/Biotin</a></p>
<p><a href="http://www.ancell.com/store/item/222">anti-CD26/FITC</a></p>
<p><a href="http://www.ancell.com/store/item/223">anti-CD26/Phycoerythrin</a></p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/14</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>Citrullinated Protein and RA</title>
				<link>http://www.ancell.com/posts//13</link>
				<comments>http://www.ancell.com/posts//13#comments</comments>
				<pubDate>Thu, 12 Apr 2012 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//13</guid>
				<description><![CDATA[<h3>A link found between autoimmune antibody specificity to Citrullinated Protein and development of Rheumatoid Arthritis.</h3>
<h3><a href="http://www.jimmunol.org/content/188/7/3542.abstract">&ldquo;Production of Autoantibodies against Citrullinated Antigens/Peptides by Human B Cells&rdquo;&nbsp; Maria F. Bellatin, Peter Stastny, et al. (2012) <em>J Immunol</em> <strong>188</strong>(7): 3542-3550</a></h3>
<h3></h3>
<p>Ancell has a large selection of Biotinylated anti-human monoclonal antibodies which would be useful for sorting and/or identifying human B cell populations:</p>
<p><a href="http://www.ancell.com/store/item/66">anti-CD2</a></p>
<p><a href="http://www.ancell.com/store/item/160">anti-CD14</a></p>
<p><a href="http://www.ancell.com/store/item/169">anti-CD16</a></p>
<p><a href="http://www.ancell.com/store/item/274">anti-CD36</a></p>
<p><a href="http://www.ancell.com/store/item/303">anti-CD43</a></p>
<p><a href="http://www.ancell.com/store/item/26">anti-CD235a</a></p>
<p><a href="http://www.ancell.com/store/item/226">anti-CD27</a></p>
<p><a href="http://www.ancell.com/store/item/283">anti-CD38</a></p>
<p><a href="http://www.ancell.com/store/item/100">anti-CD5</a></p>
<p><a href="http://www.ancell.com/store/item/186">anti-CD19</a></p>]]></description>
				<content:encoded><![CDATA[<h3>A link found between autoimmune antibody specificity to Citrullinated Protein and development of Rheumatoid Arthritis.</h3>
<h3><a href="http://www.jimmunol.org/content/188/7/3542.abstract">&ldquo;Production of Autoantibodies against Citrullinated Antigens/Peptides by Human B Cells&rdquo;&nbsp; Maria F. Bellatin, Peter Stastny, et al. (2012) <em>J Immunol</em> <strong>188</strong>(7): 3542-3550</a></h3>
<h3></h3>
<p>Ancell has a large selection of Biotinylated anti-human monoclonal antibodies which would be useful for sorting and/or identifying human B cell populations:</p>
<p><a href="http://www.ancell.com/store/item/66">anti-CD2</a></p>
<p><a href="http://www.ancell.com/store/item/160">anti-CD14</a></p>
<p><a href="http://www.ancell.com/store/item/169">anti-CD16</a></p>
<p><a href="http://www.ancell.com/store/item/274">anti-CD36</a></p>
<p><a href="http://www.ancell.com/store/item/303">anti-CD43</a></p>
<p><a href="http://www.ancell.com/store/item/26">anti-CD235a</a></p>
<p><a href="http://www.ancell.com/store/item/226">anti-CD27</a></p>
<p><a href="http://www.ancell.com/store/item/283">anti-CD38</a></p>
<p><a href="http://www.ancell.com/store/item/100">anti-CD5</a></p>
<p><a href="http://www.ancell.com/store/item/186">anti-CD19</a></p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/13</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>Leptin affects Treg populations in SLE</title>
				<link>http://www.ancell.com/posts//12</link>
				<comments>http://www.ancell.com/posts//12#comments</comments>
				<pubDate>Mon, 19 Mar 2012 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//12</guid>
				<description><![CDATA[<p>Levels of the proinflammatory leptin correlated inversely with expansion of CD25+CD4+Foxp3+ T regulatory cells in a Systemic Lupus Erythematosus mouse model (NZB/W).&nbsp; This could lead to a leptin-based immunotherapy.<a href="http://www.jimmunol.org/content/188/5/2070.abstract">&rdquo;Cutting Edge: Fasting Induced Hypoleptinemia Expands Functional Regulatory T cells in Systemic Lupus Erythematosus&rdquo;Yaoyang Liu, Yiyun Yu, Antonio La Cava, (2012) <em>J Immunol</em> <strong>188</strong>: 2070-2073.</a></p>
<p>&nbsp;Relevant Ancell Products:</p>
<p>&nbsp;<a href="http://www.ancell.com/store/search?s=anti-CD25">anti-Human CD25 products</a></p>
<p>&nbsp;<a href="http://www.ancell.com/store/search?s=anti-CD4">anti-Human CD4 products</a></p>
<p>&nbsp;<a href="http://www.ancell.com/store/search?s=anti-Mouse+CD4">anti-Mouse CD4 antibody reagents</a></p>]]></description>
				<content:encoded><![CDATA[<p>Levels of the proinflammatory leptin correlated inversely with expansion of CD25+CD4+Foxp3+ T regulatory cells in a Systemic Lupus Erythematosus mouse model (NZB/W).&nbsp; This could lead to a leptin-based immunotherapy.<a href="http://www.jimmunol.org/content/188/5/2070.abstract">&rdquo;Cutting Edge: Fasting Induced Hypoleptinemia Expands Functional Regulatory T cells in Systemic Lupus Erythematosus&rdquo;Yaoyang Liu, Yiyun Yu, Antonio La Cava, (2012) <em>J Immunol</em> <strong>188</strong>: 2070-2073.</a></p>
<p>&nbsp;Relevant Ancell Products:</p>
<p>&nbsp;<a href="http://www.ancell.com/store/search?s=anti-CD25">anti-Human CD25 products</a></p>
<p>&nbsp;<a href="http://www.ancell.com/store/search?s=anti-CD4">anti-Human CD4 products</a></p>
<p>&nbsp;<a href="http://www.ancell.com/store/search?s=anti-Mouse+CD4">anti-Mouse CD4 antibody reagents</a></p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/12</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>SLAM receptors infulence TH17 Differentialtion in SLE</title>
				<link>http://www.ancell.com/posts//11</link>
				<comments>http://www.ancell.com/posts//11#comments</comments>
				<pubDate>Fri, 03 Feb 2012 00:00:00 -0600</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//11</guid>
				<description><![CDATA[<p><a href="http://www.jimmunol.org/content/188/3/1206.abstract">&nbsp;Increased Expression of CD229(SLAMF3) and CD352(SLAMF6)</a></p>
<p><a href="http://www.jimmunol.org/content/188/3/1206.abstract">&nbsp;in SLE T Lymphocytes Promotes Th17 Differentiation</a></p>
<p>Chatterjee M., G.C. Tsokos, et al. (2012) <em>J Immunol</em> <strong>188:</strong> 1206-1212.</p>]]></description>
				<content:encoded><![CDATA[<p><a href="http://www.jimmunol.org/content/188/3/1206.abstract">&nbsp;Increased Expression of CD229(SLAMF3) and CD352(SLAMF6)</a></p>
<p><a href="http://www.jimmunol.org/content/188/3/1206.abstract">&nbsp;in SLE T Lymphocytes Promotes Th17 Differentiation</a></p>
<p>Chatterjee M., G.C. Tsokos, et al. (2012) <em>J Immunol</em> <strong>188:</strong> 1206-1212.</p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/11</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>Killer Islet Cells!</title>
				<link>http://www.ancell.com/posts//10</link>
				<comments>http://www.ancell.com/posts//10#comments</comments>
				<pubDate>Tue, 06 Dec 2011 00:00:00 -0600</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//10</guid>
				<description><![CDATA[<p>Transplanted islet cells were biochemically modified to protect their own long term engraftment in a mouse pancreas.&nbsp; These cells have the super-ability to cause apoptosis to occur in the infiltrating pathogenic T cells. &nbsp;This is a novel approach to diabetes treatment!&nbsp;</p>
<p><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Pancreatic%20Islets%20Engineered%20with%20SA-FasL%20Protein%20Establish%20Robust%20Localized%20Tolerance%20by%20Inducing%20Regulatory%20T%20Cells%20in%20Mice">&rdquo;Pancreatic Islets Engineered with SA-FasL Protein Establish Robust Localized Tolerance by Inducing Regulatory T Cells in Mice&rdquo; E.S. Yolcu, H. Shirwan, et al. (2011) <em>J Immunol</em> <strong>187</strong>: 5901-5909</a></p>]]></description>
				<content:encoded><![CDATA[<p>Transplanted islet cells were biochemically modified to protect their own long term engraftment in a mouse pancreas.&nbsp; These cells have the super-ability to cause apoptosis to occur in the infiltrating pathogenic T cells. &nbsp;This is a novel approach to diabetes treatment!&nbsp;</p>
<p><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Pancreatic%20Islets%20Engineered%20with%20SA-FasL%20Protein%20Establish%20Robust%20Localized%20Tolerance%20by%20Inducing%20Regulatory%20T%20Cells%20in%20Mice">&rdquo;Pancreatic Islets Engineered with SA-FasL Protein Establish Robust Localized Tolerance by Inducing Regulatory T Cells in Mice&rdquo; E.S. Yolcu, H. Shirwan, et al. (2011) <em>J Immunol</em> <strong>187</strong>: 5901-5909</a></p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/10</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>CD30-CD153 and CD134(OX40)-CD252 co stimulatory pathways are essential for CD4 dependant autoimmunity</title>
				<link>http://www.ancell.com/posts//9</link>
				<comments>http://www.ancell.com/posts//9#comments</comments>
				<pubDate>Tue, 01 Nov 2011 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//9</guid>
				<description><![CDATA[<h3><a href="http://jem.rupress.org/content/208/8/1579">&ldquo;Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice&rdquo;&nbsp; FM Gaspal, PJL Lane, et al. (2011) JEM 208(8): 1579-1584</a>.&nbsp;</h3>
<h3>Ancell related products</h3>
<p><a href="http://www.ancell.com/store/search?s=CD30">Blocking anti-human CD30 mAb</a></p>
<p>Recombinant &nbsp;human <a href="http://www.ancell.com/store/search?s=CD134%28OX40%29-muIg">CD134</a> and <a href="http://www.ancell.com/store/search?s=CD252%28OX40L%29-muCD8">CD252</a> Proteins</p>
<p>Anti-human <a href="http://www.ancell.com/store/search?s=anti-CD134">CD134</a> and <a href="http://www.ancell.com/store/search?s=anti-CD252">CD252</a> mAbs</p>]]></description>
				<content:encoded><![CDATA[<h3><a href="http://jem.rupress.org/content/208/8/1579">&ldquo;Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice&rdquo;&nbsp; FM Gaspal, PJL Lane, et al. (2011) JEM 208(8): 1579-1584</a>.&nbsp;</h3>
<h3>Ancell related products</h3>
<p><a href="http://www.ancell.com/store/search?s=CD30">Blocking anti-human CD30 mAb</a></p>
<p>Recombinant &nbsp;human <a href="http://www.ancell.com/store/search?s=CD134%28OX40%29-muIg">CD134</a> and <a href="http://www.ancell.com/store/search?s=CD252%28OX40L%29-muCD8">CD252</a> Proteins</p>
<p>Anti-human <a href="http://www.ancell.com/store/search?s=anti-CD134">CD134</a> and <a href="http://www.ancell.com/store/search?s=anti-CD252">CD252</a> mAbs</p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/9</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>Travel Awards for GLIIFCA 2011</title>
				<link>http://www.ancell.com/posts//8</link>
				<comments>http://www.ancell.com/posts//8#comments</comments>
				<pubDate>Thu, 29 Sep 2011 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//8</guid>
				<description><![CDATA[<p>Ancell and <a href="http://heliocyte.com/">Heliocyte </a>are proud to sponsor <a href="http://gliifca.org/travelandposterawards.html">travel and poster award</a> stipends for <a href="http://gliifca.org/gliifca20.html">Great Lakes International Imaging and Flow Cytometry Association</a> 2011 conference in Oconomowoc, WI!</p>]]></description>
				<content:encoded><![CDATA[<p>Ancell and <a href="http://heliocyte.com/">Heliocyte </a>are proud to sponsor <a href="http://gliifca.org/travelandposterawards.html">travel and poster award</a> stipends for <a href="http://gliifca.org/gliifca20.html">Great Lakes International Imaging and Flow Cytometry Association</a> 2011 conference in Oconomowoc, WI!</p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/8</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>The need to better understand Treg plasticity and function in the context of autoimmunity</title>
				<link>http://www.ancell.com/posts//7</link>
				<comments>http://www.ancell.com/posts//7#comments</comments>
				<pubDate>Mon, 12 Sep 2011 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//7</guid>
				<description><![CDATA[<p>S. Alice Long and Jane H. Buckner &ldquo;CD4+ FOXP3+ T Regulatory cells in Human Autoimmunity: More than a Numbers Game&rdquo;</p>
<p><a href="http://www.jimmunol.org/content/187/5/2061.abstract">J Immunol (2011) 187:2061-2066</a></p>]]></description>
				<content:encoded><![CDATA[<p>S. Alice Long and Jane H. Buckner &ldquo;CD4+ FOXP3+ T Regulatory cells in Human Autoimmunity: More than a Numbers Game&rdquo;</p>
<p><a href="http://www.jimmunol.org/content/187/5/2061.abstract">J Immunol (2011) 187:2061-2066</a></p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/7</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>CD30 and CD134 receptors are necessary for CD4 dependent autoimmune tissue damage</title>
				<link>http://www.ancell.com/posts//6</link>
				<comments>http://www.ancell.com/posts//6#comments</comments>
				<pubDate>Thu, 25 Aug 2011 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//6</guid>
				<description><![CDATA[<p><em><a href="http://jem.rupress.org/content/early/2011/07/21/jem.20101484">Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice.&nbsp; Gaspal F.M., P.J.L Lane, et al. (2011) JEM <strong>208</strong>(8): 1579-1584.</a></em></p>
<p>&nbsp;</p>
<p><strong>Ancell Products</strong></p>
<p><a href="http://www.ancell.com/store/item/240">anti-human CD30 antibody products</a></p>
<p><a href="http://www.ancell.com/store/item/640">anti-human CD134(OX40) antibody products</a></p>
<p><a href="http://www.ancell.com/store/item/725">anti-human CD252(OX40L) antibody products</a></p>
<p><a href="http://www.ancell.com/store/item/769">Recombinant human CD134(OX40)</a></p>
<p><a href="http://www.ancell.com/store/item/766">Recombinant human CD252(OX40L)</a></p>]]></description>
				<content:encoded><![CDATA[<p><em><a href="http://jem.rupress.org/content/early/2011/07/21/jem.20101484">Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice.&nbsp; Gaspal F.M., P.J.L Lane, et al. (2011) JEM <strong>208</strong>(8): 1579-1584.</a></em></p>
<p>&nbsp;</p>
<p><strong>Ancell Products</strong></p>
<p><a href="http://www.ancell.com/store/item/240">anti-human CD30 antibody products</a></p>
<p><a href="http://www.ancell.com/store/item/640">anti-human CD134(OX40) antibody products</a></p>
<p><a href="http://www.ancell.com/store/item/725">anti-human CD252(OX40L) antibody products</a></p>
<p><a href="http://www.ancell.com/store/item/769">Recombinant human CD134(OX40)</a></p>
<p><a href="http://www.ancell.com/store/item/766">Recombinant human CD252(OX40L)</a></p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/6</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>New anti-Mouse CD4 PE-Cy7 conjugate</title>
				<link>http://www.ancell.com/posts//5</link>
				<comments>http://www.ancell.com/posts//5#comments</comments>
				<pubDate>Fri, 05 Aug 2011 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//5</guid>
				<description><![CDATA[<p><a href="http://www.ancell.com/store/item/869">New anti-Mouse CD4 PE-Cy7 conjugate available now!</a></p>
<p>Watch for more PE-Cy7 conjugates available soon.</p>]]></description>
				<content:encoded><![CDATA[<p><a href="http://www.ancell.com/store/item/869">New anti-Mouse CD4 PE-Cy7 conjugate available now!</a></p>
<p>Watch for more PE-Cy7 conjugates available soon.</p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/5</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>Ancell announces partnership with HelioCyte!</title>
				<link>http://www.ancell.com/posts//4</link>
				<comments>http://www.ancell.com/posts//4#comments</comments>
				<pubDate>Mon, 23 May 2011 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//4</guid>
				<description><![CDATA[<p><strong>Ancell announces partnership with <a href="http://www.heliocyte.com">HelioCyte</a> to provide cutting edge Flow Cytometry products!</strong></p>
<p><br /><strong>Watch for new products designed to simplify and improve your Flow research!</strong></p>
<div><strong>Twitter account:&nbsp; Heliocyte</strong></div>]]></description>
				<content:encoded><![CDATA[<p><strong>Ancell announces partnership with <a href="http://www.heliocyte.com">HelioCyte</a> to provide cutting edge Flow Cytometry products!</strong></p>
<p><br /><strong>Watch for new products designed to simplify and improve your Flow research!</strong></p>
<div><strong>Twitter account:&nbsp; Heliocyte</strong></div>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/4</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>anti-Mouse CD4/DyLight350 conjugate</title>
				<link>http://www.ancell.com/posts//3</link>
				<comments>http://www.ancell.com/posts//3#comments</comments>
				<pubDate>Wed, 18 May 2011 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//3</guid>
				<description><![CDATA[<p>Improved multi-color staining of Mouse tissues</p>
<p>Anti-Mouse CD4 (clone GK1.5)/DyLight350*&nbsp; conjugate now available!</p>
<p>&nbsp; <a href="http://www.ancell.com/store/item/858">Catalog #704-350</a></p>
<p>DyLight350* is excitable by Near-UV laser Amax 353, and emits in the blue range, Emax 432nm.</p>
<p>Look for more DyLight350 conjugates available soon!</p>]]></description>
				<content:encoded><![CDATA[<p>Improved multi-color staining of Mouse tissues</p>
<p>Anti-Mouse CD4 (clone GK1.5)/DyLight350*&nbsp; conjugate now available!</p>
<p>&nbsp; <a href="http://www.ancell.com/store/item/858">Catalog #704-350</a></p>
<p>DyLight350* is excitable by Near-UV laser Amax 353, and emits in the blue range, Emax 432nm.</p>
<p>Look for more DyLight350 conjugates available soon!</p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/3</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>CD134(OX40) Signaling Mechanism Elucidated</title>
				<link>http://www.ancell.com/posts//2</link>
				<comments>http://www.ancell.com/posts//2#comments</comments>
				<pubDate>Wed, 20 Apr 2011 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//2</guid>
				<description><![CDATA[<p>Engagement of CD134(OX40) by its Ligand (CD252) induces an intracellular signaling complex which&nbsp; includes PKB, and PI3K, and requires TRAF2.</p>
<p><a href="http://www.jimmunol.org/content/186/6/3547.abstract">Takanori S, H Choi, M Croft. (2011) <em>J Immunol</em> <strong>186</strong>(6):3547-3555.</a></p>
<p>&nbsp;</p>
<p><strong>Ancell Products:</strong></p>
<p><a href="http://www.ancell.com/store/item/770">Recombinant human CD134-muIg Fusion protein</a></p>
<p><a href="http://www.ancell.com/store/item/766">Recombinant human CD252(OX40)-muCD8</a></p>
<p><a href="http://www.ancell.com/store/item/640">Monoclonal anti-human CD134(OX40)</a></p>
<p><a href="http://www.ancell.com/store/item/725">Monoclonal anti-human CD252(OX40L)</a></p>
<p>&nbsp;</p>]]></description>
				<content:encoded><![CDATA[<p>Engagement of CD134(OX40) by its Ligand (CD252) induces an intracellular signaling complex which&nbsp; includes PKB, and PI3K, and requires TRAF2.</p>
<p><a href="http://www.jimmunol.org/content/186/6/3547.abstract">Takanori S, H Choi, M Croft. (2011) <em>J Immunol</em> <strong>186</strong>(6):3547-3555.</a></p>
<p>&nbsp;</p>
<p><strong>Ancell Products:</strong></p>
<p><a href="http://www.ancell.com/store/item/770">Recombinant human CD134-muIg Fusion protein</a></p>
<p><a href="http://www.ancell.com/store/item/766">Recombinant human CD252(OX40)-muCD8</a></p>
<p><a href="http://www.ancell.com/store/item/640">Monoclonal anti-human CD134(OX40)</a></p>
<p><a href="http://www.ancell.com/store/item/725">Monoclonal anti-human CD252(OX40L)</a></p>
<p>&nbsp;</p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/2</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
						<item>
				<title>CD28 Superagonist protects against Rheumatoid Arthritis mediated bone destruction</title>
				<link>http://www.ancell.com/posts//1</link>
				<comments>http://www.ancell.com/posts//1#comments</comments>
				<pubDate>Wed, 30 Mar 2011 00:00:00 -0500</pubDate>
				<dc:creator>Ancell Corporation</dc:creator>
						
				<guid isPermaLink="true">http://www.ancell.com/posts//1</guid>
				<description><![CDATA[<p><strong>In mice, use of CD28 superagonist has been shown to increase the % of  Treg cells, and&nbsp;protect from Rheumatoid Arthritis mediated bone  destruction.</strong><br /><a href="http://www.jimmunol.org/content/184/12/7238.abstract">Marlo M Zaiss, Jean-Pierre David, et al. (2010) <em>J Immunol </em><strong>184</strong>: 7238-7246.</a></p>
<p><a href="http://www.ancell.com/store/search?s=anti-CD28">Ancell anti-CD28 antibody clone ANC28.1/5D10</a> has been <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001708">characterized</a> as a superagonist.</p>
<p>This mAb has been found to be <a href="http://www.ancell.com/repository/1/832/anc28_1_stimulation.pdf">capable</a> of stimulating IL-2 production from Jurkat cells without T Cell Receptor engagement.</p>
<p><a href="http://www.jimmunol.org/content/176/10/5725.full">Cutting Edge: Monovalency of CD28 Maintains the Antigen Dependence of T Cell Costimulatory Responses</a><strong><a href="http://www.jimmunol.org/content/176/10/5725.full"><br /></a></strong>Kevin M. Dennehy, Thomas H&uuml;nig, et al. <em>The Journal of Immunology</em>, 2006, <strong>176</strong>: 5725-5729.</p>]]></description>
				<content:encoded><![CDATA[<p><strong>In mice, use of CD28 superagonist has been shown to increase the % of  Treg cells, and&nbsp;protect from Rheumatoid Arthritis mediated bone  destruction.</strong><br /><a href="http://www.jimmunol.org/content/184/12/7238.abstract">Marlo M Zaiss, Jean-Pierre David, et al. (2010) <em>J Immunol </em><strong>184</strong>: 7238-7246.</a></p>
<p><a href="http://www.ancell.com/store/search?s=anti-CD28">Ancell anti-CD28 antibody clone ANC28.1/5D10</a> has been <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001708">characterized</a> as a superagonist.</p>
<p>This mAb has been found to be <a href="http://www.ancell.com/repository/1/832/anc28_1_stimulation.pdf">capable</a> of stimulating IL-2 production from Jurkat cells without T Cell Receptor engagement.</p>
<p><a href="http://www.jimmunol.org/content/176/10/5725.full">Cutting Edge: Monovalency of CD28 Maintains the Antigen Dependence of T Cell Costimulatory Responses</a><strong><a href="http://www.jimmunol.org/content/176/10/5725.full"><br /></a></strong>Kevin M. Dennehy, Thomas H&uuml;nig, et al. <em>The Journal of Immunology</em>, 2006, <strong>176</strong>: 5725-5729.</p>]]></content:encoded>
				<wfw:commentRss>http://www.ancell.com/posts/rss.xml/1</wfw:commentRss>
				<slash:comments>0</slash:comments>
			</item>
			
</channel>
</rss>